Landos Biopharma, Inc. (LABP)

22.47 +0.12 (+0.54%) At close: 04:00PM EDT

Landos Biopharma, Inc.

PO Box 11239
Blacksburg, VA 24062
United States
540-218-2232
https://landosbiopharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 19

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Gregory Oakes	President, CEO & Director	1.05M	N/A	1969
Dr. Fabio Cataldi M.D.	Executive VP & Chief Medical Officer	732.29k	N/A	1968
Ms. Jennifer Creel	Interim Chief Financial Officer	N/A	N/A	1971
Ms. Rebecca Mosig Ph.D.	Vice President of Corporate Development	N/A	N/A	N/A
Dr. Josep Bassaganya-Riera DVM, Ph.D.	Advisor	1.79M	N/A	1975

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia.

Corporate governance

Landos Biopharma, Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.